Skip to main content
. Author manuscript; available in PMC: 2013 Apr 20.
Published in final edited form as: Immunity. 2012 Apr 20;36(4):542–550. doi: 10.1016/j.immuni.2012.03.014

Table 1.

Selected JAKinibs

Agent Targets Indication/Phase
Tofacitinib JAK3/JAK1/JAK2 RA/Phase III
Psoriasis/Phase II
IBD/Phase II
VX-509 JAK3 RA/Phase II
R-348 JAK3 RA/Phase I
Ruxolitinib JAK1/JAK2 Approved – MF/PV
INCB-28050 JAK1/JAK2 RA/Phase II
GLPG-0634 JAK1 RA/Phase II
AC-430 JAK2 RA/Phase I
Lymphoma/Phase I
Lestaurtinib FLT3/TrkA/JAK2 AML/Phase III
Psoriasis/Phase II
Pancreatic cancer/Phase II
CEP-33779 JAK2 Preclinical